hENT1 Antibody

Datasheet

For Research Use Only

Description	Catalog No.	Size
hENT1 Concentrate	FP-A060-01	0.1 ml
hENT1 Concentrate	FP-A060-05	1 ml
hENT1 Predilute	FP-A060-70	7 ml

Description

The Human Equilibrative Nucleoside Transporter 1 (hENT1) mediates the cellular uptake of physiologic nucleosides, including adenosine, as well as many anti-cancer drugs including gemcitabine, cytarabine, and decitabine. Deficiency of hENT1 can lead to resistance of such drugs, and the abundance of hENT1 protein in the plasma membrane is a major indicator of the efficiency and clinical outcome of these anti-cancer nucleosides.

Specifications

Clone	IHC595
Source	Mouse Monoclonal
Applications	IHC (P)
Formulation	Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide

IHC Procedure*

Positive Control Tissue	Adrenal Cortex, Kidney, Thyroid, Tonsil, Normal Pancreas
Concetrated Dilution	1:50 – 1:200
Pretreatment	Perform heat-induced epitope retrieval (HIER) at pH 9 for 10 to 30 minutes
Incubation Time and Temp	10 to 30 minutes at room temperature
Detection	Refer to the detection system manual

*Result should confirmed by an established diagnostic procedure.

Result



Figure. hENT1 on Thyroid Cancer

Website：www.femtopath.com Tel：+886 2 32338585
E-mail： femtopath@hongjing.com.tw Fax：+886 2 32338686
Address：5F., No.172, Sec. 1, Zhongshan Rd., Yonghe Dist., New Taipei City 234, Taiwan (R.O.C)

Storage and Handling

Must store the reagent at 2-8 °C. Do not freeze. Do not use the reagent after expiration date on vial. To ensure proper stability and delivery of the antibody after each run, replace the cap and immediately place the bottle in a refrigerator in an upright position. Positive and negative controls should be simultaneously run with unknown specimens, as there are no conclusive characteristics to suggest instability of the antibody.

Precautions

The product is for research use only. Do not use for diagnosis purpose. Ensure proper handling procedures are used with all reagents. Always wear laboratory coats, disposable gloves, and other appropriate laboratory equipment when handling reagents. Do not ingest reagents, and avoid contact with eyes and mucous membranes. Wash eyes with copious amounts of water if contact occurs.

References

1. **Chow L**, et al. "Analysis of human equilibrative nucleoside transporter 1 (hENT1) protein in non-Hodgkin's lymphoma by immunohistochemistry." Mod Pathol. 2005 Apr;18(4):558-64.
2. **Santini D**, et al. "Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC)." Curr Cancer Drug Targets. 2011; 11:123-9.
3. **Sundaram M**, et al. "Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs." J Biol Chem. 2001; 276:45270-5.
4. **Borbath I**, et al. "Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma." Eur J Cancer. 2012; 48:990-6.
5. **Greenhalf W**, et al. "Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial." J Natl Cancer Inst. 2014; 106:djt347.
6. **Wu L**, et al. "High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome." J Transl Med. 2016; 14:66.

Technical Support

Contact FemtoPath Technical Support at +886232338585 or email to femtopath@hongjing.com.tw for questions regarding this product.